Researchers have discovered a new way to target and kill cancer cells in hard-to-treat brain tumors using electrically charged molecules to trigger self-destruction, that could be developed into a spray treatment used during surgery.
What Coherus’ $40M sale of its Humira biosimilar says about the crowded market
Coherus BioSciences is selling its Humira biosimilar for just $40 million, only three years after it won FDA approval, showing just how crowded the market
June 28, 2024